Matrix metalloproteinases and their inhibitors in ovarian cancer progression - diagnostic and therapeutic implications;Rola metaloproteaz macierzowych i ich inhibitorów w progresji raka jajnika - implikacje diagnostyczne i terapeutyczne

Ginekologia Polska

Volumn 80, Issue 1, 2009, Pages 47-53

  Rafał, Stettner ^a   Michał, Bogusiewicz ^a   Tomasz, Rechberger ^a  

^a II Katedra i Klinika Ginekologii   (Poland)

Author keywords

Metalloproteinases; Ovarian cancer; Tissue inhibitors of metalloproteinase

Indexed keywords

COLLAGENASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER;

BLOOD; ENZYMOLOGY; FEMALE; HUMAN; OVARY TUMOR; PROGNOSIS; REVIEW;

COLLAGENASES; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 64549127803     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Krajowy Rejestr Chorób Nowotworowych, 2000.
2. Egeblad M, Werb Z. New functions for the matrix matalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2, 163-174.
3. Wojtowicz-Praga S, Dickson R, Hawkins M. Matrix metalloproteinase inhibitors. Invest New Drugs. 1997, 15, 61-75.
4. Borkakoti N. Structural studies of matrix metalloproteinases. J Mol Med. 2000. 78, 261-268.
5. Leppert D, Lindberg RLP, Kappos L, [et al.]. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev. 2001, 36, 249-257.
6. Hartung H, Kieseier B. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol. 2000, 107, 140-147.
7. Butler G, Butler M, Atkinson S, [et al.]. The TIMP 2 membrane type 1 metaloproteinase "receptor" regulates the concetration and efficient activation of progelatinase A. A kinetic study. J.Biol Chem. 1998, 273, 871-880.
8. Kinoshita T, Sato H, Okada A, [et al.]. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immoblized on agarose beads.J.Biol Chem. 1998, 273. 16098-16103.
9. Westermarck J, Kaharii V. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13, 781-792.
10. Coussens L, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996, 3, 895-904.
11. Woessner J Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5, 2145-2154.
12. Nagase H, Woessner J Jr. Matrix metalloproteinases. J Biol Chem. 1999, 274, 21491-21494.
13. Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. Bioessays. 2005, 27, 1181-1191.
14. Butler G, Will H, Atkinson S, [et al.]. Membrane -type -2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997, 244, 653-657.
15. Zhao W, Li H, Yamashita K. [et al.]. Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases -1 (TIMP-1) in the nuclei of human gingival fibroblasts. J Cell Sci. 1998, 111, 1147-1153.
16. Hayakawa T, Yamashita K, Ohuchi E, [et al.]. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 ( TIMP-2). J Cell Sci. 1994, 107, 2373-2379.
17. Boujrad N, Ogwuegbu S, Garnier M, [et al.]. Identyfication of a stimular for of steroid hormone synthesis isolated from testis. Science. 1995, 268, 1609-1612.
18. Murphy A, Unsworth E, Stetler-Stevenson W. Tissue inhibitor of metalloproteinases- 2 inhibits bFGF- induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993, 157, 351-358.
19. Li G, Fridman R, Kim H. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999, 59, 6267-6275.
20. Valente P, Fassina G, Melchiori A, [et al.]. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998, 75, 246-253.
21. Westermarck J, Kalahari V. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13, 781-792.
22. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000, 36, 1621-1630.
23. Coussens L, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996, 3, 895-904.
24. Koblinski J, Ahram M, Sloane B. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000, 291,113-135.
25. Yurchenco P, Schittny J. Molecular architecture of basement membranes. FASEB J. 1990, 4, 1577-1590.
26. Liotta L, Tryggvason, Garbisa S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980, 284, 67-68.
27. Barsky S, Siegal G, Jannotta F: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest. 1983, 49, 140-147.
28. Schnaper H, Grant D, Stetler-Stevenson W. Type IV collagenase(s) and TIMPs modulate endothelial cells morphogenesis in vitro. J Cell Physiol. 1993, 156, 235-246.
29. Fang J, Shing Y, Wiederschain D, [et al.]. Matrix meatalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA. 2000, 97, 3884-3889.
30. Ascar A, Onan A, Coskun U, [et al.]. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med Oncol. 2008, 25, 279-283.
31. Sillanpaa S, Anttila M, Suhonen K, [et al.]. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metallopoteinase 2 in epithelial ovarian cancer. Tumor Biol. 2007, 28, 280-289.
32. Maatta M, Santala M, Soini Y, [et al.]. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol. 2004, 25, 188-192.
33. Sakata K, Shigemasa K, Nagai N. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors ( TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000, 17, 673-681.
34. Huang L, Garrett A, Bell D, [et al.]. Differential expression of matrix metalloproteinase - 9 and tissue inhibitor of metalloproteinase- 1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 2000, 77, 369-376.
35. Schmalfeldt B, Prechtel D, Härting K, [et al.]. Increased expression of matrix metallo- proteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001, 7, 2396-2404.
36. Ripley D, Tunuguntla R, Susi L, [et al.]. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma. Int J Gynecol Cancer. 2006, 16, 1794-1800.
37. Mueller J, Brebeck B, Schmalfeldt B, [et al.]. Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch. 2000, 437, 618-624.
38. Shigemasa K, Tanimoto H, Sakata K, [et al.]. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol. 2000, 17, 52-58.
39. Wang F, So J, Reierstad S. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005, 114, 19-31.
40. Kim T, Rho S, Choi Y, [et al.]. High expression of tissue inhibitor of metalloproteinase- 2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol. 2006, 37, 906-913.
41. Cai K, Yang W, Capo-Chichi C, [et al.]. Prominent expression of metalloproteinases in early stages of ovarian tumorgenesis. Mol Carcinog. 2007, 46, 130-143.
42. Davidson B, Reich R, Berner A. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer. 2001, 37, 2040-2049.
43. Behrens P, Rothe M, Florin A, [et al.]. Invasive properties of serum human epithelial ovarian tumors are related to Ets- 1, MMP-1 and MMP-2 expression. Int J Mol Med. 2001, 8, 149-154.
44. Boyd R, Balkwill F. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer. 1999, 80, 315-321.
45. Kenny H, Kaur S, Coussens L, [et al.]. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008, 118,1367-1379.
46. Sakata K, Shigemasa K, Uebaba Y, [et al.]. Expression of matrix metalloproteinases-2 and -9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. Acta Cytol. 2002, 46, 697-703.
47. Belotti D, Paganoni P, Manenti L, [et al.]. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003, 63, 5224-5229.
48. Schmalfeldt B, Prechtel D, Härting K, [et al.]. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001, 7, 2396-2404.
49. Davidson B, Goldberg I, Berner A, [et al.]. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol. 2001, 115, 517-524.
50. Yabushita H, Shimazu M, Noguchi M. Vascular endothelial growth factor activating matrix metalloproteinase in ascetic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003, 10, 89-95.
51. Sood A, Fletcher M, Coffin J, [et al.]. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004, 190, 899-909.
52. Maatta M, Talvensaari -Mattila A, Turpeenniemi Hujanen T, [et al.]. Matrix metalloproteinase -2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential ( LMP) and malignant ovarian tumours. Anticancer Res. 2007, 27, 2753-2758.
53. Manenti L, Paganoni P, Floriani I, [et al.]. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003, 39, 1948-1956.
54. Garzetti G, Ciavattini A, Lucarini G, [et al.]. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125. Anticancer Res. 1996, 16, 2123-2127.
55. Bazzett L, Magnus M, Taylor D, [et al.]. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecol Oncol. 2003. 90, 435-442.
56. Kanamori Y, Matsushima M, Minaguchi T, [et al.]. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999, 59, 4225-4227.
57. Ju W, Kim JW, Park N, [et al.]. Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer:does ethnicity matter? J Obstet Gynaecol Res. 2007, 33, 155-160.
58. Szyllo K, Smolarz B, Romanowicz-Makowska H, [et al.]. The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J Exp Clin Cancer Res. 2002, 21, 357-361.
59. Wenham R, Calingaert B, Ali S, [et al.]. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig. 2003, 10, 381-387.
60. Li Y, Jin X, Kang S, Wang Y, [et al.]. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol. 2006, 101, 92-96.
61. Davidson B, Goldberg I, Gotlieb W, [et al.]. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol. 2002, 187, 39-45.
62. Sillanpää S, Anttila M, Voutilainen K, [et al.]. .Prognostic significance of matrix metallo- proteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer. 2006, 119, 1792-1799.
63. Sillanpää S, Anttila M, Voutilainen K, [et al.]. Prognostic significance of matrix metallo- proteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 2007, 104, :296- 303.
64. Perigny M, Bairati I, Harvey I, [et al.]. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol. 2008, 129, 226-231.
65. Demeter A, Sziller I, Csapo Z, [et al.]. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res. 2005, 25, 2885-2889.
66. Lengyel E, Schmalfeldt B, Konik E, [et al.]. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001, 82, 291-298.
67. Wu X, Li H, Kang L, [et al.]. Activated matrix metalloproteinase-2 -a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol. 2002, 84, 126-134.
68. Six L, Grimm C, Leodolter S, [et al.]. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol. 2006, 100, 506-510.
69. Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictiveas well as a prognostic factor. Gynecol Oncol. 2005, 99, 656-663.
70. Lin S, Lee M, Ke F, [et al.]. TGF beta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis. 2000, 18, 493-499.
71. Giavazzi R, Garofalo A, Ferri C, [et al.]. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998, 4, 985-992.
72. Heath E, O'Reilly S, Humphrey R, [et al.]. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001, 48, 269-274.
73. Erlichman C, Adjei A, Alberts S, [et al.]. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001, 12, 389-395.
74. Macaulay V, O'Byrne K, Saunders M. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 1999, 5, 513-520.
75. Costa S, von Minckwitz G, Wernicke K, [et al.]. New aspects by the therapy of ovarian cancer- What changes after the ASCO-Meeting 2001. Zentralbl Gynakol. 2002, 124, 96-103.